Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.955 USD | +2.99% | +2.60% | -30.82% |
May. 07 | Transcript : AbCellera Biologics Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | AbCellera Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Evolution of the average Target Price on AbCellera Biologics Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering AbCellera Biologics Inc.
Benchmark Company | |
Stifel Nicolaus | |
KeyBanc Capital Markets | |
Piper Sandler | |
Goldman Sachs | |
Berenberg Bank | |
Credit Suisse | |
Cowen | |
BMO Capital | |
SVB Securities LLC | |
Truist Securities | |
SVB Leerink | |
Benchmark Capital |
EPS Revisions
- Stock Market
- Equities
- ABCL Stock
- Consensus AbCellera Biologics Inc.